On the stock market since 2004, it operates in the world of health and science. It has 382 employees. Now — the numbers.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly above the class average — a step short of the very top.
The price looks reasonable next to what the company earns.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades 38% below its peak. The market has trimmed its expectations for the company.
It pays out $1.25 per share each year — regular cash for whoever holds the stock.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 36/100. For a turnaround signal, the stock first needs to close the gap with the market.
The sales tempo runs behind the sector. Council score: 4/10.
On our five-subject report card, SPOK sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: SPOK is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.